Why might thiazolidinediones increase exercise capacity in patients with type 2 diabetes?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Effects of glucose-lowering agents on cardiorespiratory fitness.World journal of diabetes · 2018
   Review
2. The effect of exercise training combined with PPARγ agonist on skeletal muscle glucose uptake and insulin sensitivity in induced diabetic obese Zucker rats.Journal of exercise nutrition & biochemistry · 2016
   Article
3. Impaired microvascular perfusion: a consequence of vascular dysfunction and a potential cause of insulin resistance in muscle.American journal of physiology. Endocrinology and metabolism · 2008 · on this map
   Review
4. Daily Patterns of Physical Activity by Type 2 Diabetes Definition: Comparing Diabetes, Prediabetes, and Participants with Normal Glucose Levels in NHANES 2003-2006.Preventive medicine reports
   Article

Corrections and comments

• Comment on
  Rosiglitazone improves exercise capacity in individuals with type 2 diabetes.2005

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as